



FOR IMMEDIATE RELEASE:

**EYEGATE PHARMA'S CEO TO PARTICIPATE AT UPCOMING
INVESTOR AND OPHTHALMOLOGY CONFERENCES**

Waltham, MA – October 29, 2007 – EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that Stephen From, President and Chief Executive Officer, will present a corporate update at the *Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference* and attend the *American Academy of Ophthalmology's 2007 Annual Meeting*. Mr. From will be available for one-on-one meetings during both conferences.

The *Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference* will be held at the New York Palace Hotel in New York, NY, from November 5 - 7, 2007. Mr. From will present on Monday, November 5 at 12:20 PM in the Hubbard room. For more information, please visit <http://www.rodmanandrenshaw.com/conferences?id=6>

The American Academy of Ophthalmology's 2007 Annual Meeting will be held in New Orleans, LA, from November 10 - 13, 2007. For more information, please visit http://www.aao.org/meetings/annual_meeting/index.cfm

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate[®] II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies utilizing the EyeGate[®] II Delivery System are scheduled to begin in 2008. For more information please visit www.eyegatepharma.com

#

Contact:

Martin Reynolds
LaVoie Group
978-745-4200 X107
mreynolds@lavoiegroup.com